{"id":"W3211871096","doi":"10.1182/blood-2021-147614","title":"A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Adverse effect; Population; Clinical trial; Phases of clinical research; Surgery; Pediatrics; Bone marrow","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022981,0.001790859,0.002478974,0.0004128916,0.0005249057,0.001460161,0.001200986,0.002022892,0.008163095],"category_scores_gemma":[0.002096738,0.0007201411,0.002314892,0.0003540353,0.001301426,0.001445714,0.0004855426,0.004511167,0.001283645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001019015,"about_ca_system_score_gemma":0.001332307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001021566,"about_ca_topic_score_gemma":0.003058488,"domain_scores_codex":[0.9993611,0.0003394055,0.00002876112,0.0001200473,0.00003853806,0.0001122682],"domain_scores_gemma":[0.9985789,0.0003706973,0.0002382134,0.0001205278,0.00008351167,0.0006081218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9798451,0.007898507,0.0004829409,0.0002246841,0.0005456361,0.00004734458,0.00003960975,0.0003067178,0.001418603,0.00008353798,0.001008291,0.008099011],"study_design_scores_gemma":[0.9457048,0.05193049,0.001004913,0.00001550649,0.0002094077,0.00004081982,0.00001582887,0.0004196309,0.0001628086,0.0001137659,0.0003703773,0.00001166092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851081,0.003340349,0.0006098701,0.001272971,0.0009694158,0.004067547,0.001618456,0.0001750261,0.002838312],"genre_scores_gemma":[0.9876757,0.001245864,0.00131905,0.001793677,0.00049726,0.003174586,0.001808101,0.00002726959,0.002458549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008163095,"threshold_uncertainty_score":0.02730829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02224321597315307,"score_gpt":0.2714861247213994,"score_spread":0.2492429087482463,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}